Idiopathic hypersomnia is characterized by excessive daytime sleepiness. It is often mistaken for narcolepsy. In addition to its psychiatric symptoms, it can overlap with narcolepsy and affect the ability to work and interact socially. Unfortunately, there is currently no FDA-approved treatment for idiopathic hypersomnia, which leaves many people with chronic insomnia unproductive.
Idiopathic hypersomnia is a rare neurologic disorder that affects people’s ability to sleep. People with the disorder tend to experience excessive daytime sleepiness, resulting in difficulty waking up in the morning. In severe cases, the patient may also struggle to awaken and may even take a nap during the day. Patients may also appear drunk or confused, or have difficulty concentrating during the day.
The global idiopathic hypersomnia treatment market is estimated to be valued at US$ 242.4 million in 2021 and is expected to exhibit a CAGR of 8.7% over the forecast period (2022-2028).
Get Free Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
Rising incidence of lifestyle diseases such as anxiety, depression, etc. caused by behavioral changes, social activities, which affects the sleep cycle is the key factor responsible for growth of the global idiopathic hypersomnia treatment market. These changes lead to anxiety, depression, & other health issues, in which patients feel tired during the daytime and are more prone to hypersomnia. For instance, according to the Anxiety and Depression Association of America, anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults in the U.S. of age 18 and older, or 18.1% of the population every year.
Furthermore, growing diagnosis rate of hypersomnia coupled with technological advancements for diagnosis of hypersomnia are other major factor expected to fuel growth of the global idiopathic hypersomnia treatment market. For instance, multiple sleep latency test (MSLT) is the standard tool used to diagnose narcolepsy and idiopathic hypersomnia, which is offered at AASM-accredited sleep centers in the U.S.
Growing number of pipeline products for idiopathic hypersomnia treatment is also a major factor that is projected to boost growth of the global idiopathic hypersomnia treatment market. For instance, in January 2020, Millennium Pharmaceuticals, Inc., a subsidiary of Takeda Pharmaceutical Company Limited initiated the phase1 study of a single intravenous infusion dose of TAK-925 in participants with idiopathic hypersomnia.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 45 million infected individuals worldwide as of October 30, 2020. Due to the increasing prevalence of COVID-19, key players operating in the idiopathic hypersomnia treatment market are focusing on research and development of novel products to support and combat the effect of COVID-19. COVID-19 pandemic has impacted the global economy and in turn, the idiopathic hypersomnia treatment market. Quarantines, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending until the end of the third quarter of 2020
Global Idiopathic Hypersomnia Treatment Market – Restraint
Side effects of drug such as aggressive behavior & dependence and no approved product are some of the key factors that are expected to restrict growth of the global idiopathic hypersomnia treatment market. Moreover, declining less patient pool for clinical trials is also a major setback for the global idiopathic hypersomnia treatment market, which is expected to hinder growth of the market.
Request PDF Brochure with Latest Insights @
Major players operating in the global idiopathic hypersomnia treatment market include Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., BIOPROJET, Avadel Pharmaceuticals, Plc. GlaxoSmithKline plc, Pfizer Inc., Theranexus, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, and Merck & Co. Inc.
Reasons to buy this Idiopathic Hypersomnia Treatment Market Report
◘ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Idiopathic Hypersomnia Treatment Market
◘ Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Idiopathic Hypersomnia Treatment Market
◘ Leading company profiles reveal details of key Idiopathic Hypersomnia Treatment Market players emerging five operations and financial performance
◘ Add weight to presentations and pitches by understanding the future growth prospects of the emerging Idiopathic Hypersomnia Treatment Market with five year historical forecasts
◘ Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Idiopathic Hypersomnia Treatment Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Idiopathic Hypersomnia Treatment Market are also given.
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Idiopathic Hypersomnia Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Idiopathic Hypersomnia Treatment Industry Impact
Chapter 2 Global Idiopathic Hypersomnia Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Idiopathic Hypersomnia Treatment (Volume and Value) by Type
2.3 Global Idiopathic Hypersomnia Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Idiopathic Hypersomnia Treatment Sales, Consumption, Export, Import by Regions
Chapter 5 North America Idiopathic Hypersomnia Treatment Market Analysis
Chapter 6 East Asia Idiopathic Hypersomnia Treatment Market Analysis
Chapter 7 Europe Idiopathic Hypersomnia Treatment Market Analysis
Chapter 8 South Asia Idiopathic Hypersomnia Treatment Market Analysis
Chapter 9 Southeast Asia Idiopathic Hypersomnia Treatment Market Analysis
Chapter 10 Middle East Idiopathic Hypersomnia Treatment Market Analysis
Chapter 11 Africa Idiopathic Hypersomnia Treatment Market Analysis
Chapter 12 Oceania Idiopathic Hypersomnia Treatment Market Analysis
Chapter 13 South America Idiopathic Hypersomnia Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Idiopathic Hypersomnia Treatment Business
Chapter 15 Global Idiopathic Hypersomnia Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027